

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TransThera Sciences (Nanjing), Inc.
藥捷安康（南京）科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2617)

DATE OF BOARD MEETING

The board of directors (the “**Board**”) of TransThera Sciences (Nanjing), Inc. (the “**Company**”) hereby announces that a meeting of the Board will be held on Monday, 25 August 2025 for the purposes of, amongst other matters, (i) considering and approving the unaudited consolidated interim results of the Company and its subsidiaries for the six months ended 30 June 2025 and its publication thereof; (ii) considering the declaration and payment of an interim dividend, if any; and (iii) transacting any other business.

By Order of the Board
TransThera Sciences (Nanjing), Inc.
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, 13 August 2025

As at the date of this announcement, the Board comprises Dr. Frank Wu and Mr. Wu Di as executive Directors; Ms. Jia Zhongxin and Dr. Yi Hua as non-executive Directors; and Ms. Chui Hoi Yam, Ms. Zheng Zhelan and Mr. Li Shu Pai as independent non-executive Directors.